258 related articles for article (PubMed ID: 32169861)
1. Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention
Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Utsumi T; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T;
Br J Ophthalmol; 2020 Dec; 104(12):1755-1761. PubMed ID: 32169861
[TBL] [Abstract][Full Text] [Related]
2. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.
Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Kotake O; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T;
Br J Ophthalmol; 2020 Sep; 104(9):1209-1215. PubMed ID: 31784500
[TBL] [Abstract][Full Text] [Related]
3. Monotherapy laser photocoagulation for diabetic macular oedema.
Jorge EC; Jorge EN; Botelho M; Farat JG; Virgili G; El Dib R
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010859. PubMed ID: 30320466
[TBL] [Abstract][Full Text] [Related]
4. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
Mikhail M; Stewart S; Seow F; Hogg R; Lois N
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
[TBL] [Abstract][Full Text] [Related]
5. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study.
Granstam E; Rosenblad A; Modher Raghib A; Granström T; Eriksson JW; Lindholm Olinder A; Leksell J
Acta Ophthalmol; 2020 Jun; 98(4):360-367. PubMed ID: 31656056
[TBL] [Abstract][Full Text] [Related]
7. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
8. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.
Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T
Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425
[TBL] [Abstract][Full Text] [Related]
9. Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab.
Talks SJ; Bhatia D; Menon G; Cole A; Eleftheriadis H; Downey L; Chong NV; Sivaprasad S;
Eye (Lond); 2019 Jun; 33(6):930-937. PubMed ID: 30728488
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.
Prünte C; Fajnkuchen F; Mahmood S; Ricci F; Hatz K; Studnička J; Bezlyak V; Parikh S; Stubbings WJ; Wenzel A; Figueira J;
Br J Ophthalmol; 2016 Jun; 100(6):787-95. PubMed ID: 26453639
[TBL] [Abstract][Full Text] [Related]
11. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
12. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema.
Lang GE; Liakopoulos S; Vögeler J; Weiß C; Spital G; Gamulescu MA; Lohmann C; Wiedemann P
Acta Ophthalmol; 2018 May; 96(3):e377-e385. PubMed ID: 29090846
[TBL] [Abstract][Full Text] [Related]
13. Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.
Wong Y; Steel DHW; Habib MS; Stubbing-Moore A; Bajwa D; Avery PJ;
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):733-742. PubMed ID: 27957600
[TBL] [Abstract][Full Text] [Related]
14. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema.
Gerendas BS; Prager S; Deak G; Simader C; Lammer J; Waldstein SM; Guerin T; Kundi M; Schmidt-Erfurth UM
Br J Ophthalmol; 2018 Feb; 102(2):195-203. PubMed ID: 28724636
[TBL] [Abstract][Full Text] [Related]
15. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes.
Ciulla TA; Pollack JS; Williams DF
Br J Ophthalmol; 2021 Feb; 105(2):216-221. PubMed ID: 32265201
[TBL] [Abstract][Full Text] [Related]
16. Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity.
Busch C; Okada M; Zur D; Fraser-Bell S; Rodríguez-Valdés PJ; Cebeci Z; Lupidi M; Fung AT; Gabrielle PH; Giancipoli E; Chaikitmongkol V; Laíns I; Santos AR; Kunavisarut P; Sala-Puigdollers A; Chhablani J; Ozimek M; Hilely A; Degenhardt V; Loewenstein A; Iglicki M; Rehak M;
Acta Ophthalmol; 2020 Nov; 98(7):e801-e806. PubMed ID: 32115886
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab for the Treatment of Diabetic Macular Oedema in the Real-World Clinical Setting in Portugal: A Multicentre Study.
Farinha C; Martins A; Neves A; Soares R; Ruão M; Ornelas M; Neves P; Gomes Rodrigues F; Coelho C; Silva R
Ophthalmologica; 2019; 241(1):1-8. PubMed ID: 29886497
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
19. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data.
Gonzalez VH; Campbell J; Holekamp NM; Kiss S; Loewenstein A; Augustin AJ; Ma J; Ho AC; Patel V; Whitcup SM; Dugel PU
Am J Ophthalmol; 2016 Dec; 172():72-79. PubMed ID: 27644589
[TBL] [Abstract][Full Text] [Related]
20. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.
Chang CK; Cheng CK; Peng CH
Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]